Market Cap (In AUD)
142.14 Million
Revenue (In AUD)
65.8 Thousand
Net Income (In AUD)
-58.65 Million
Avg. Volume
720.97 Thousand
- Currency
- AUD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.165-0.61
- PE
- -
- EPS
- -
- Beta Value
- 0.874
- ISIN
- AU000000PAR5
- CUSIP
- Q7269W102
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC
- Employee Count
- -
- Website
- https://www.paradigmbiopharma.com
- Ipo Date
- 2015-08-19
- Details
- Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
More Stocks
-
RNFT
-
SCTSFScottie Resources Corp.
SCTSF
-
0298
-
900140LVMC Holdings
900140
-
ALCOFCofidur S.A.
ALCOF
-
PREV-BPrevas AB
PREV-B
-
OPNOponeo.pl S.A.
OPN
-
SNV-PDSynovus Financial Corp.
SNV-PD